Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

NexusPharma

NexusPharma
M&A STATUS
M&A LATEST DEAL TYPE
1 INVESTORS
Description

Operator of drug discovery company intended for the discovery of innovative anti-cancer treatments. The company is dedicated to the discovery of novel therapeutics by creating and testing patient-derived cancer xenograft models, enabling health professionals to enhance the predictive value of its models for clinical outcomes.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Outcome Management (Healthcare)
Parent Company
Genesis Drug Discovery & Development
Primary Office
  • Fox Chase Cancer Center, Room P2017
  • 333 Cottman Avenue
  • Philadelphia, PA 19111
  • United States

+1 (732) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore NexusPharma’s full profile, request a free trial.

NexusPharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 18-Jun-2019 Completed Generating Revenue
1. Seed Round 04-May-2005 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

NexusPharma Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Ben Franklin Technology Partner of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0

NexusPharma Executive Team (2)

Name Title Board
Seat
Contact
Info
Lutz Weber Ph.D Co-Founder, Chief Executive Officer & President
Vladimir Khazak Ph.D Co-Founder & Chief Scientific Officer

NexusPharma Board Members (2)

Name Representing Role Since Contact
Info
Erica Golemis Ph.D NexusPharma Board Member 000 0000
Igor Astsaturov Ph.D NexusPharma Board Member 000 0000